# A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy

> **NCT04058704** · PHASE3 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 296 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Brain Metastases

## Interventions

- **DRUG:** Icotinib
- **RADIATION:** SRS/WBRT/HA-WBRT/SMART

## Key facts

- **NCT ID:** NCT04058704
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-20
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 296 (ESTIMATED)
- **Last updated:** 2019-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04058704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04058704, "A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04058704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*